Major step forward in cannabis production

THE GOOD OIL: Rhizo Sciences, who Hikurangi Group have signed with, specialise in extraction labs and manufacturing facilities to produce cannabis flower and oil products, as well as pharmaceutical-grade medicines.

RUATORIA-based Hikurangi Group has signed an agreement to work with Rhizo Sciences LLC, a cannabis industry development company based in Seattle, Washington.

Hikurangi Group and Rhizo Sciences intend to establish the first pharmaceutical-grade GMP medical cannabis production and processing facility in New Zealand.

This will allow Hikurangi Group to provide high-quality medical cannabis products to New Zealand patients and become a leading producer and processor of medical cannabis internationally.

Rhizo Sciences develops and manages medical cannabis cultivation, extraction and manufacturing facilities internationally.

Its international experience and systems will enable Hikurangi Group to rapidly expand its Ruatoria medical cannabis cultivation operations and develop export manufacturing capability that meets international standards for pharmaceutical grade products.

Rhizo Sciences works with licensed processors and investors to develop large-scale production and export facilities to supply the growing demand for medical cannabis and cannabidiol (CBD) products internationally.

The company specialises in CO2 extraction labs and manufacturing facilities to produce cannabis flower and oil products, as well as pharmaceutical-grade medicines.

The company is developing a global network of growers, manufacturers and distributors of wholesale cannabis flower, extracts and cannabis medicines to distribute internationally, including the United States, Canada, Australia, Israel, Europe, the United Kingdom, Africa and South America. To meet demand it is developing facilities in strategically positioned new markets.

Hikurangi Hemp managing director Manu Caddie says this agreement is great timing. An offer is being taken to investors next month.

“Having a partner with deep industry knowledge and global customers provides exciting opportunities for our young company. This relationship will enable us to export product potentially worth tens of millions every year.”

Auckland investment brokers Northington Partners are taking the Hikurangi offer to institutional investors in February.

Northington director Nick Sandlant agrees the partnership will only add value to the capital- raising.

“We already have strong interest in this offer, the first opportunity to invest in a New Zealand medical cannabis venture from crop to consumer. The relationship with Rhizo Sciences, their wholesale customers and producer partners around the world should give investors even more confidence in the potential of Hikurangi Group to deliver proven medicines to New Zealand patients and customers around the world.”

Rhizo Sciences co-founder and president Dr Dallas McMillan says his company was attracted to Hikurangi Group for two reasons.

“Hikurangi have demonstrated their commitment to world-class production standards and the clinical trials they have planned for this year will be world-leading. We want to be able offer our customers clean, green New Zealand product and an integrated company like Hikurangi Group offers the perfect partner.”

The facility will begin manufacturing THC-free CBD products in 2018, with a plan to produce a full range of pharmaceutical-grade medical cannabis products for local patients and worldwide export.

RUATORIA-based Hikurangi Group has signed an agreement to work with Rhizo Sciences LLC, a cannabis industry development company based in Seattle, Washington.

Hikurangi Group and Rhizo Sciences intend to establish the first pharmaceutical-grade GMP medical cannabis production and processing facility in New Zealand.

This will allow Hikurangi Group to provide high-quality medical cannabis products to New Zealand patients and become a leading producer and processor of medical cannabis internationally.

Rhizo Sciences develops and manages medical cannabis cultivation, extraction and manufacturing facilities internationally.

Its international experience and systems will enable Hikurangi Group to rapidly expand its Ruatoria medical cannabis cultivation operations and develop export manufacturing capability that meets international standards for pharmaceutical grade products.

Rhizo Sciences works with licensed processors and investors to develop large-scale production and export facilities to supply the growing demand for medical cannabis and cannabidiol (CBD) products internationally.

The company specialises in CO2 extraction labs and manufacturing facilities to produce cannabis flower and oil products, as well as pharmaceutical-grade medicines.

The company is developing a global network of growers, manufacturers and distributors of wholesale cannabis flower, extracts and cannabis medicines to distribute internationally, including the United States, Canada, Australia, Israel, Europe, the United Kingdom, Africa and South America. To meet demand it is developing facilities in strategically positioned new markets.

Hikurangi Hemp managing director Manu Caddie says this agreement is great timing. An offer is being taken to investors next month.

“Having a partner with deep industry knowledge and global customers provides exciting opportunities for our young company. This relationship will enable us to export product potentially worth tens of millions every year.”

Auckland investment brokers Northington Partners are taking the Hikurangi offer to institutional investors in February.

Northington director Nick Sandlant agrees the partnership will only add value to the capital- raising.

“We already have strong interest in this offer, the first opportunity to invest in a New Zealand medical cannabis venture from crop to consumer. The relationship with Rhizo Sciences, their wholesale customers and producer partners around the world should give investors even more confidence in the potential of Hikurangi Group to deliver proven medicines to New Zealand patients and customers around the world.”

Rhizo Sciences co-founder and president Dr Dallas McMillan says his company was attracted to Hikurangi Group for two reasons.

“Hikurangi have demonstrated their commitment to world-class production standards and the clinical trials they have planned for this year will be world-leading. We want to be able offer our customers clean, green New Zealand product and an integrated company like Hikurangi Group offers the perfect partner.”

The facility will begin manufacturing THC-free CBD products in 2018, with a plan to produce a full range of pharmaceutical-grade medical cannabis products for local patients and worldwide export.

Your email address will not be published. Comments will display after being approved by a staff member. Comments may be edited for clarity.

Clive Bibby - 10 months ago
Well done Manu and your team. I am impressed with what you have accomplished to date.
I have always believed that we need to give credit where it is clearly due and it would appear that you have overcome a mountain of roadblocks to reach this stage so, as a fellow traveller in that arena who understands those difficulties, my compliments are in order.
I am still rather nervous about how these products will be distributed and maintained only as a useful pain relief substitute that can be a valuable addition to medicines already available. I guess it will be the responsibility of the government health regulatory authorities to require the introduction of safeguards to assure folk like me that your remedies will not become available to people who shouldn't be using them.
I, like others, have taken on board your earlier assurances that your product doesn't have the addictive qualities of the dope we are feeding to our vulnerable kids with disastrous results.
So, I am prepared to give you the benefit of the doubt on this issue until we see the positive benefits for sufferers that you claim will be the direct result of their introduction.
I believe that through sheer hard work and dilligence, you have earned the right to pursue your objectives by taking the investigations to the next level and am supportive of that development.
Good luck.

Poll

  • Voting please wait...
    Your vote has been cast. Reloading page...
    Do you think that schools 'poaching' rugby players by offering them scholarships is OK?